Patents Represented by Attorney, Agent or Law Firm Rosemarie Wilk-Orescan
  • Substituted piperazines and diazepanes
    Patent number: 7208497
    Abstract: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: April 24, 2007
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dorwald, Knud Erik Andersen, Jan Lindy Sørensen
  • Nucleic acids encoding aggrecan degrading metallo proteases
    Patent number: 6521436
    Abstract: The invention is directed to the family of aggrecan degrading metallo proteases (ADMPs) that exhibit the ability to cleave the aggrecan core protein between amino acid residues Glu373-Ala374. The invention encompasses the nucleic acids encoding such enzymes, processes for production of recombinant ADMPs, compositions containing such enzymes, and the use of these enzymes in various assays and for the development of novel inhibitors for use as therapies for diseases involving aggrecanase-mediated degradation of cartilage or other aggrecanase-associated diseases.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Elizabeth C. Arner, Timothy C. Burn, Robert A. Copeland, Carl P. Decicco, Ruiqin Liu, Ronald Magolda, Michael Pratta, Kimberly A. Solomon, Micky D. Tortorella, James M. Trzaskos, Fude Yang
  • Method for screening compounds to identify beta-amyloid production modulators
    Patent number: 6518011
    Abstract: The present invention is directed generally to methods and composition for monitoring the processing of epitope-tagged beta-APP. More specifically, the present invention relates to the use of such methods and composition for monitoring responses of cells expressing such epitope-tagged beta-APP or fragments thereof or cell free systems containing the epitope-tagged polypeptides to therapy of diseases associated with an altered metabolism of the beta amyloid precursor protein (APP), and for screening and evaluation of potential drugs for the treatment of these disorders, including Alzheimer's disease (AD).
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: February 11, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dietmar A. Seiffert, Thomas J. Mitchell
  • Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
    Patent number: 6346517
    Abstract: This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: February 12, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Pancras C. Wong, Shaker A. Mousa
  • Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
    Patent number: 6238695
    Abstract: The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: May 29, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: William T. Makooi-Morehead, John D. Buehler, Brian R. Landmann
  • N-adamant-1-y1-N1-[4-chlorobenzothiazol-2-y1] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
    Patent number: 6214851
    Abstract: This invention relates generally to N-adamant-1-yl-N′-[4-chlorobenzothiazol-2-yl] urea, pharmaceutical compositions comprising the same, and methods of using the same in the treatment of inflammation and as an anticancer radiosensitizing agent.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: April 10, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: John J. V. Duncia, Daniel S. Gardner, IV, Joseph B Santella, III